Paper21189397
How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials.
Kiely BE and 3 others. J Clin Oncol, 2011. Cited by 112 papers, by iCite.
Cite this record
ConductScience Library. How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials. Papers, record 21189397. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/21189397
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials.
- PubMed
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Breast Neoplasms | Major topic |
| Disease-Free Survival | |
| Female | |
| Humans | |
| Middle Aged | |
| Neoplasm Invasiveness | |
| Randomized Controlled Trials as Topic | |
| Risk Assessment | |
| Risk Factors | |
| Survival Analysis | |
| Survival Rate | |
| Time Factors | |
| Treatment Outcome |
Source PubMed
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 21189394 | Simple rules can improve prognostic accuracy. | https://conductscience.org/library/papers/21189394 |
Source PubMed
Cited by51
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 112 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41613559 | Ocular metastasis in breast cancer: management of clinical case reports and a literature review. | Front Oncol | 2025 | https://conductscience.org/library/papers/41613559 | PubMed |
| 40125267 | A mixed methods pilot study of a serious illness communication training curriculum among medical residents. | Palliat Care Soc Pract | 2025 | https://conductscience.org/library/papers/40125267 | PubMed |
| 39614657 | Survival scenarios of patients with localized and metastatic pancreatic adenocarcinoma: A population-based study. | Int J Cancer | 2025 | https://conductscience.org/library/papers/39614657 | PubMed |
| 38768122 | Estimating scenarios for survival time in patients with advanced melanoma receiving immunotherapy and targeted therapy. | Oncologist | 2024 | https://conductscience.org/library/papers/38768122 | PubMed |
| 37963058 | Accuracy of oncologists' estimates of expected survival time in advanced cancer. | JNCI Cancer Spectr | 2023 | https://conductscience.org/library/papers/37963058 | PubMed |
| 37935631 | Circulating Tumor Cells Prediction in Hormone Receptor Positive HER2-Negative Advanced Breast Cancer: A Retrospective Analysis of the MONARCH 2 Trial. | Oncologist | 2024 | https://conductscience.org/library/papers/37935631 | PubMed |
| 37781156 | Effect of a prediction tool and communication skills training on communication of treatment outcomes: a multicenter stepped wedge clinical trial (the SOURCE trial). | EClinicalMedicine | 2023 | https://conductscience.org/library/papers/37781156 | PubMed |
| 37296790 | Real-World Outcomes of CDK4/6 Inhibitors Treatment in Metastatic Breast Cancer in Romania. | Diagnostics (Basel) | 2023 | https://conductscience.org/library/papers/37296790 | PubMed |
| 37104871 | A 6-Week Program to Strengthen Resiliency Among Women With Metastatic Cancer: A Randomized Clinical Trial. | Oncologist | 2023 | https://conductscience.org/library/papers/37104871 | PubMed |
| 36547132 | Optimal Choice as First-Line Therapy for Patients with Triple-Negative Breast Cancer: A Bayesian Network Meta-Analysis. | Curr Oncol | 2022 | https://conductscience.org/library/papers/36547132 | PubMed |
| 35880940 | Current State of Cell Therapies for Breast Cancer. | Cancer J | 2022 | https://conductscience.org/library/papers/35880940 | PubMed |
| 35871393 | Voluntary assisted dying: estimating life expectancy to determine eligibility. | Med J Aust | 2022 | https://conductscience.org/library/papers/35871393 | PubMed |
| 35701634 | Using three scenarios to explain life expectancy in advanced cancer: attitudes of patients, family members, and other healthcare professionals. | Support Care Cancer | 2022 | https://conductscience.org/library/papers/35701634 | PubMed |
| 35278078 | Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation. | Oncologist | 2022 | https://conductscience.org/library/papers/35278078 | PubMed |
| 34830936 | Prognostic Value of Prospective Longitudinal CRP to Albumin Ratio among Older Outpatients with Cancer. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34830936 | PubMed |
| 34553322 | Does ComPsych Communication Skills Training Alter Trainee Self-Efficacy? | Acad Psychiatry | 2022 | https://conductscience.org/library/papers/34553322 | PubMed |
| 34448703 | Informing Patients With Esophagogastric Cancer About Treatment Outcomes by Using a Web-Based Tool and Training: Development and Evaluation Study. | J Med Internet Res | 2021 | https://conductscience.org/library/papers/34448703 | PubMed |
| 34267656 | Efficacy and Safety of Anti-PD-1/ PD-L1 Monotherapy for Metastatic Breast Cancer: Clinical Evidence. | Front Pharmacol | 2021 | https://conductscience.org/library/papers/34267656 | PubMed |
| 34043434 | Decision Making in Older Adults With Cancer. | J Clin Oncol | 2021 | https://conductscience.org/library/papers/34043434 | PubMed |
| 33880062 | Disparities in Guideline-Concordant Initial Systemic Treatment in Women with HER2-Negative Metastatic Breast Cancer: A SEER-Medicare Analysis. | Breast Cancer (Dove Med Press) | 2021 | https://conductscience.org/library/papers/33880062 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ERBB2 | 2064 | PubTator's text mining | https://conductscience.org/library/genes/2064 | NCBI Gene |
| ESR1 | 2099 | PubTator's text mining | https://conductscience.org/library/genes/2099 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/21189397
GET https://conductscience.org/api/papers/v1/21189397/cited_by?page=2